Is ACB a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on International medical cannabis growth, with revenue (ttm) at ~314M (Canadian dollars), down ~9% YoY in the latest quarter. The bear case rests on the central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

International medical cannabis growth. Aurora's clearest strength is fast-growing international medical cannabis, its highest-margin business, led by Germany and Poland and extending to Australia and New Zealand.

The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. The takeover contest adds a new kind of volatility: if Curaleaf's offer lapses or is withdrawn and no alternative deal emerges, the shares could give back much of the roughly 49% three-month gain, while holders who tender would mostly receive Curaleaf stock, carrying that company's own risks. Even after the medical turnaround, management guided fiscal 2027 EBITDA lower, partly due to reduced Canadian medical reimbursement rates from April 2026, and revenue fell about 9% year over year in the June 2026 quarter. As a small-cap in a small, fast-changing industry, Aurora is heavily exposed to regulation: a policy change in Germany, Poland, Canada, or any key market can swing results quickly, and the whole sector is prone to sharp sentiment-driven moves. Currency swings between the Canadian dollar, euro, and US dollar affect reported results. Competition from Tilray, Canopy Growth, Curaleaf and local European producers is intense. The shares are volatile and speculative, and the stock has no dividend.

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (International medical cannabis growth) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice; Walnut is not an investment adviser. The bull case is Aurora's pivot to fast-growing, higher-margin international medical cannabis, its debt-free balance sheet, and takeover interest that values it above the current price. The bear case is a long history of dilution and reverse splits, continuing GAAP losses, lower fiscal 2027 EBITDA guidance, the chance the bid lapses, and heavy dependence on regulation in a small, volatile sector. This is a speculative small-cap, so weigh both sides carefully against your portfolio.

Aurora is a Canadian licensed cannabis producer that grows, manufactures, and sells cannabis, now focused mainly on global medical cannabis. It supplies EU-GMP certified medical product into international markets such as Germany, Poland, Australia, and New Zealand, and has exited most of its lower-margin Canadian recreational and non-core businesses. Its results increasingly reflect medical demand rather than the Canadian consumer market it was once known for.

Aurora is a small-cap in a small, fast-changing, heavily regulated industry, so its shares move sharply on news about regulation, earnings, and sector sentiment. In 2026 alone it traded between about $2.56 and $6.36, and the Curaleaf bid pushed it up about 49% over three months. Add a history of equity raises and reverse splits, and the result is a stock capable of large, rapid moves in both directions.